bioRxiv Science⌕ Search

Biology subjects

Rebiffe, L.

Publications and source records attributed to Rebiffe, L..

2 recordsLinked to original sources

Liver FGF21 mediates sex-specific adaptation to juvenile protein malnutrition

Dietary protein sufficiency during childhood is essential for healthy growth and tissue development. Chronic protein deficiency leads to stunting, height-for-age more than two standard deviations below the median, and affects 149 million children under five (https://www.who.int/publications/i/item/9789240073791). Linear growth is governed by the somatotropic axis, wherein pituitary growth hormone (GH) stimulates hepatic insulin-like growth factor 1 (IGF-1) to promote bone elongation1. Although boys are consistently more stunted than girls across populations (ranging from 18% to 45%)2,3, mechanisms underlying this apparent resilience remain unclear. Rodent studies suggest that the protein-to-carbohydrate ratio modulates life-history traits such as metabolism, lifespan, and reproduction, with evidence of sex-dependent sensitivity4,5. Whether such dimorphism reflects coordinated developmental adaptations in response to protein scarcity, particularly in females, has not been fully explored. Here, we show that juvenile dietary protein restriction causes sexually dimorphic adaptations with pronounced stunting in males and delayed reproductive maturation in females. Using liver-specific deletion, we identify fibroblast growth factor 21 (FGF21) as a sex-specific hepatic regulator of female somatic growth and reproductive development, revealing a dimorphic endocrine adaptation to early-life protein scarcity. Our findings position FGF21 as a critical physiological checkpoint coordinating growth and reproductive timing in response to nutritional stress.

physiology↗

Semaglutide interferes with postnatal growth in a diet-dependent manner

GLP-1 receptor agonists, including semaglutide, are increasingly used to treat obesity--and to a lesser extent, type 2 diabetes--in children and adolescents. Despite their therapeutic promise, the impact of semaglutide on key endocrine and metabolic developmental processes during this period is not yet fully understood. To address the limited understanding of GLP-1 receptor agonists during development, we investigated the effects of chronic semaglutide treatment on growth and metabolism of weanling male mice. In juvenile mice displaying a normal growth pattern, semaglutide lowered blood glucose without affecting food intake or weight gain. In contrast, chronic semaglutide treatment in growth-stunted juveniles exacerbated linear growth impairment, despite preserving glucose-lowering effects. Transcriptomic analysis of the liver, complemented by gene expression studies in other metabolically active tissues, suggested altered energy expenditure, indicating a complex interaction between semaglutide, energy metabolism, and growth during juvenile development. These findings underscore the importance of developmental context when evaluating the safety and efficacy of GLP-1 receptor agonists in pediatric populations.

physiology↗